{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:15:05Z","timestamp":1785802505966,"version":"3.56.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The Vice-Chancellery of Research and Technology of Shiraz University of Medical Sciences financially supported this study","award":["27326"],"award-info":[{"award-number":["27326"]}]},{"name":"The Vice-Chancellery of Research and Technology of Shiraz University of Medical Sciences financially supported this study","award":["27326"],"award-info":[{"award-number":["27326"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00210-024-03372-5","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T10:03:01Z","timestamp":1727085781000},"page":"2945-2960","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Protective effects of silymarin on preventing vancomycin nephrotoxicity in infectious patients: a randomized, double-blinded, placebo-controlled, pilot clinical trial"],"prefix":"10.1007","volume":"398","author":[{"given":"Ava","family":"Karimian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Karimzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojtaba","family":"Shafiekhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Masjedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Izadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazanin","family":"Barshan-Tashnizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra L.","family":"Kane-Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laleh","family":"Mahmoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,23]]},"reference":[{"issue":"1","key":"3372_CR1","doi-asserted-by":"publisher","first-page":"76","DOI":"10.22088\/cjim.14.1.76","volume":"14","author":"S Abbasi","year":"2023","unstructured":"Abbasi S, Bigharaz E, Farsaei S, Mansourian M (2023) Could melatonin prevent vancomycin-induced nephrotoxicity in critically ill patients? A randomized, double-blinded controlled trial. Casp J Intern Med 14(1):76. https:\/\/doi.org\/10.22088\/cjim.14.1.76","journal-title":"Casp J Intern Med"},{"issue":"10","key":"3372_CR2","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1002\/ptr.3207","volume":"24","author":"L Abenavoli","year":"2010","unstructured":"Abenavoli L, Capasso R, Milic N, Capasso F (2010) Milk thistle in liver diseases: past, present, future. Phyther Res 24(10):1423\u201332. https:\/\/doi.org\/10.1002\/ptr.3207","journal-title":"Phyther Res"},{"issue":"2","key":"3372_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15640\/ijmp.v3n2a1","volume":"3","author":"S Akundi","year":"2015","unstructured":"Akundi S, Lee YR, Perry GK, Fike DS, Mnjoyan S (2015) Nephrotoxicity in recipients of vancomycin vs. vancomycin with vitamin C. Int J Med Pharm 3(2):1\u20135. https:\/\/doi.org\/10.15640\/ijmp.v3n2a1","journal-title":"Int J Med Pharm"},{"key":"3372_CR4","doi-asserted-by":"publisher","unstructured":"Arnaud FCS, Lib\u00f3rio AB (2020) Attributable nephrotoxicity of vancomycin in critically ill patients: a marginal structural model study. J Antimicrob Chemother 75(4):1031\u20137. https:\/\/doi.org\/10.1093\/jac\/dkz520","DOI":"10.1093\/jac\/dkz520"},{"issue":"1","key":"3372_CR5","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12882-017-0536-3","volume":"18","author":"L Awdishu","year":"2017","unstructured":"Awdishu L, Mehta RL (2017) The 6R\u2019s of drug induced nephrotoxicity. BMC Nephrol 18(1):124. https:\/\/doi.org\/10.1186\/s12882-017-0536-3","journal-title":"BMC Nephrol"},{"issue":"6","key":"3372_CR6","doi-asserted-by":"publisher","first-page":"397","DOI":"10.34172\/aim.2020.33","volume":"23","author":"S Badri","year":"2020","unstructured":"Badri S, Soltani R, Sayadi M, Khorvash F, Meidani M, Taheri S (2020) Effect of N-acetylcysteine against vancomycin-induced nephrotoxicity: a randomized controlled clinical trial. Arch Iran Med. 23(6):397\u2013402. https:\/\/doi.org\/10.34172\/aim.2020.33","journal-title":"Arch Iran Med."},{"issue":"1","key":"3372_CR7","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.phymed.2012.09.004","volume":"20","author":"L Calani","year":"2012","unstructured":"Calani L, Brighenti F, Bruni R, Del Rio D (2012) Absorption and metabolism of milk thistle flavanolignans in humans. Phytomedicine 20(1):40\u20136. https:\/\/doi.org\/10.1016\/j.phymed.2012.09.004","journal-title":"Phytomedicine"},{"issue":"3","key":"3372_CR8","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1017\/ice.2017.308","volume":"39","author":"D Chotiprasitsakul","year":"2018","unstructured":"Chotiprasitsakul D, Tamma PD, Gadala A, Cosgrove SE (2018) The role of negative methicillin-resistant Staphylococcus aureus nasal surveillance swabs in predicting the need for empiric vancomycin therapy in intensive care unit patients. Infect Control Hosp Epidemiol 39(3):290\u20136. https:\/\/doi.org\/10.1017\/ice.2017.308","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"11","key":"3372_CR9","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.3390\/molecules24112155","volume":"24","author":"A Di Costanzo","year":"2019","unstructured":"Di Costanzo A, Angelico R (2019) Formulation strategies for enhancing the bioavailability of silymarin: the state of the art. Molecules 24(11):2155","journal-title":"Molecules"},{"issue":"1","key":"3372_CR10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/kisup.2012.77","volume":"3","author":"G Eknoyan","year":"2013","unstructured":"Eknoyan G, Lameire N, Eckardt K et al (2013) KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 3(1):5\u201314","journal-title":"Kidney Int"},{"issue":"9","key":"3372_CR11","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s00228-012-1259-9","volume":"68","author":"S Elyasi","year":"2012","unstructured":"Elyasi S, Khalili H, Dashti-Khavidaki S, Mohammadpour A (2012) Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol 68(9):1243\u201355. https:\/\/doi.org\/10.1007\/s00228-012-1259-9","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"3372_CR12","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s00228-012-1406-3","volume":"69","author":"S Elyasi","year":"2013","unstructured":"Elyasi S, Khalili H, Hatamkhani S, Dashti-Khavidaki S (2013) Prevention of vancomycin induced nephrotoxicity: a review of preclinical data. Eur J Clin Pharmacol 69(4):747\u201354. https:\/\/doi.org\/10.1007\/s00228-012-1406-3","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"3372_CR13","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1053\/j.ajkd.2012.06.005","volume":"60","author":"MK Fallahzadeh","year":"2012","unstructured":"Fallahzadeh MK, Dormanesh B, Sagheb MM et al (2012) Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial. Am J Kidney Dis 60(6):896\u2013903. https:\/\/doi.org\/10.1053\/j.ajkd.2012.06.005","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"3372_CR14","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/cpt.726","volume":"102","author":"E Filippone","year":"2017","unstructured":"Filippone E, Kraft W, Farber J (2017) The nephrotoxicity of vancomycin. Clin Pharmacol Ther 102(3):459\u201369. https:\/\/doi.org\/10.1002\/cpt.726","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"3372_CR15","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/hdi.12413","volume":"20","author":"O Firuzi","year":"2016","unstructured":"Firuzi O, Khajehrezaei S, Ezzatzadegan S, Nejati M, Jahanshahi K, Roozbeh J (2016) Effects of silymarin on biochemical and oxidative stress markers in end-stage renal disease patients undergoing peritoneal dialysis. Hemodial Int 20(4):558\u201363. https:\/\/doi.org\/10.1111\/hdi.12413","journal-title":"Hemodial Int"},{"issue":"13","key":"3372_CR16","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.3389\/fphar.2022.912202","volume":"24","author":"P Ghasemiyeh","year":"2022","unstructured":"Ghasemiyeh P, Vazin A, Zand F et al (2022) Pharmacokinetic assessment of vancomycin in critically ill patients and nephrotoxicity prediction using individualized pharmacokinetic parameters. Front Pharmacol 24(13):3082. https:\/\/doi.org\/10.3389\/fphar.2022.912202","journal-title":"Front Pharmacol"},{"issue":"6","key":"3372_CR17","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1080\/01480545.2019.1584208","volume":"43","author":"S Guzel","year":"2020","unstructured":"Guzel S, Sahinogullari ZU, Canacankatan N, Antmen SE, Kibar D, Coskun YB (2020) Potential renoprotective effects of silymarin against vancomycin-induced nephrotoxicity in rats. Drug Chem Toxicol 43(6):630\u2013636. https:\/\/doi.org\/10.1080\/01480545.2019.1584208","journal-title":"Drug Chem Toxicol"},{"issue":"4","key":"3372_CR18","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3760\/cma.j.cn121430-20200110-00083","volume":"32","author":"J He","year":"2020","unstructured":"He J, Mao E, Xu W et al (2020) High dose vitamin C significantly reduces the nephrotoxicity of vancomycin in critically ill patients. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 32(4):468\u2013472. https:\/\/doi.org\/10.3760\/cma.j.cn121430-20200110-00083","journal-title":"Zhonghua Wei Zhong Bing Ji Jiu Yi Xue"},{"issue":"9","key":"3372_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/AAC.00462-21","volume":"65","author":"TS Hong","year":"2021","unstructured":"Hong TS, Briscese K, Yuan M, Deshpande K, Aleksunes LM, Brunetti L (2021) Renoprotective effects of melatonin against vancomycin-related acute kidney injury in hospitalized patients: a retrospective cohort study. Antimicrob Agents Chemother 65(9).\u00a0https:\/\/doi.org\/10.1128\/AAC.00462-21","journal-title":"Antimicrob Agents Chemother"},{"key":"3372_CR20","unstructured":"https:\/\/www.openepi.com\/Menu\/OE_Menu.htm."},{"issue":"19","key":"3372_CR21","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"Inker LA, Eneanya ND, Coresh J et al (2021) New creatinine- and cystatin C\u2013based equations to estimate GFR without race. N Engl J Med 385(19):1737\u201349. https:\/\/doi.org\/10.1056\/NEJMoa2102953","journal-title":"N Engl J Med"},{"issue":"3","key":"3372_CR22","first-page":"239","volume":"16","author":"S Javed","year":"2011","unstructured":"Javed S, Kohli K, Ali M (2011) Reassessing bioavailability of silymarin. Altern Med Rev 16(3):239","journal-title":"Altern Med Rev"},{"issue":"4","key":"3372_CR23","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.3390\/ijms23042052","volume":"23","author":"WC Kan","year":"2022","unstructured":"Kan WC, Chen YC, Wu VC, Shiao CC (2022) Vancomycin-associated acute kidney injury: a narrative review from pathophysiology to clinical application. Int J Mol Sci 23(4):2052. https:\/\/doi.org\/10.3390\/ijms23042052","journal-title":"Int J Mol Sci"},{"key":"3372_CR24","doi-asserted-by":"publisher","unstructured":"Karimian A, Mahmoudi L. Silymarin\u2019s potential in countering drug-induced cardiotoxicity, nephrotoxicity, and hepatotoxicity: a narrative review. Trends Pharm Sci. 2024;10(1). https:\/\/doi.org\/10.30476\/TIPS.2024.100638.1220","DOI":"10.30476\/TIPS.2024.100638.1220"},{"issue":"1","key":"3372_CR25","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1186\/s13054-023-04720-2","volume":"27","author":"I Karimzadeh","year":"2023","unstructured":"Karimzadeh I, Barreto EF, Kellum JA et al (2023) Moving toward a contemporary classification of drug-induced kidney disease. Crit Care 27(1):435. https:\/\/doi.org\/10.1186\/s13054-023-04720-2","journal-title":"Crit Care"},{"key":"3372_CR26","doi-asserted-by":"publisher","unstructured":"Karimzadeh I, Haghighati G, Ramzi M, Sagheb MM, Zomorodian K (2017) Assessing the epidemiology of nephrotoxicity and the role of urinary kidney injury molecule 1 as a biomarker of renal function in hematologic-oncologic patients under vancomycin treatment in Shiraz, Iran. Iran Red Crescent Med J 19(3):1\u201310. https:\/\/doi.org\/10.5812\/ircmj.40858","DOI":"10.5812\/ircmj.40858"},{"key":"3372_CR27","doi-asserted-by":"publisher","unstructured":"Karimzadeh I, Strader M, Kane-Gill SL, Murray PT (2023) Prevention and management of antibiotic associated acute kidney injury in critically ill patients: new insights. Curr Opin Crit Care 29(6):595\u2013606. https:\/\/doi.org\/10.1097\/MCC.0000000000001099","DOI":"10.1097\/MCC.0000000000001099"},{"key":"3372_CR28","unstructured":"Khalili H, Bairami S, Kargar M (2013) Antibiotics induced acute kidney injury: incidence, risk factors, onset time and outcome. Acta Med Iran 871\u20138."},{"issue":"4","key":"3372_CR29","doi-asserted-by":"publisher","first-page":"c179","DOI":"10.1159\/000339789","volume":"120","author":"A Khwaja","year":"2012","unstructured":"Khwaja A (2012) KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 120(4):c179\u2013c84. https:\/\/doi.org\/10.1159\/000339789","journal-title":"Nephron Clin Pract"},{"issue":"2","key":"3372_CR30","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/14740338.2020.1712357","volume":"19","author":"M Mahi-Birjand","year":"2020","unstructured":"Mahi-Birjand M, Yaghoubi S, Abdollahpour-Alitappeh M et al (2020b) Protective effects of pharmacological agents against aminoglycoside-induced nephrotoxicity: a systematic review. Expert Opin Drug Saf 19(2):167\u201386. https:\/\/doi.org\/10.1080\/14740338.2020.1712357","journal-title":"Expert Opin Drug Saf"},{"key":"3372_CR31","doi-asserted-by":"publisher","unstructured":"Mahi-Birjand M, Karimzadeh I, Zarban A, Abdollahpour-Alitappeh M, Saadatjoo SA, Ziaee M (2020a) Protective effects of silymarin on gentamicin-induced nephrotoxicity in infectious patients: a randomized double blinded placebo-controlled clinical trial. Pharm Sci 26(3):287\u201395. https:\/\/doi.org\/10.34172\/PS.2020.33","DOI":"10.34172\/PS.2020.33"},{"issue":"7","key":"3372_CR32","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.1007\/s11033-020-05635-9","volume":"47","author":"N Malkani","year":"2020","unstructured":"Malkani N, Naeem A, Ijaz F, Mumtaz S, Ashraf S, Sohail MI (2020) Silybum marianum (milk thistle) improves vancomycin induced nephrotoxicity by downregulating apoptosis. Mol Biol Rep 47(7):5451\u20139. https:\/\/doi.org\/10.1007\/s11033-020-05635-9","journal-title":"Mol Biol Rep"},{"issue":"6","key":"3372_CR33","doi-asserted-by":"publisher","first-page":"656","DOI":"10.5483\/BMBRep.2006.39.6.656","volume":"39","author":"HH Mansour","year":"2006","unstructured":"Mansour HH, Hafez HF, Fahmy NM (2006) Silymarin modulates cisplatin-induced oxidative stress and hepatotoxicity in rats. BMB Rep 39(6):656\u201361","journal-title":"BMB Rep"},{"issue":"2","key":"3372_CR34","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/ki.2015.115","volume":"88","author":"RL Mehta","year":"2015","unstructured":"Mehta RL, Awdishu L, Davenport A et al (2015) Phenotype standardization for drug-induced kidney disease. Kidney Int 88(2):226\u201334. https:\/\/doi.org\/10.1038\/ki.2015.115","journal-title":"Kidney Int"},{"issue":"2","key":"3372_CR35","doi-asserted-by":"publisher","first-page":"149","DOI":"10.5114\/ceh.2021.107067","volume":"7","author":"E Mirzaei","year":"2021","unstructured":"Mirzaei E, Sabetian G, Masjedi M et al (2021) The effect of silymarin on liver enzymes and antioxidant status in trauma patients in the intensive care unit: a randomized double blinded placebo-controlled clinical trial. Clin Exp Hepatol 7(2):149\u201355. https:\/\/doi.org\/10.5114\/ceh.2021.107067","journal-title":"Clin Exp Hepatol"},{"key":"3372_CR36","doi-asserted-by":"publisher","unstructured":"Murphy ME, Barreto EF. Vancomycin should be considered a nephrotoxic antimicrobial agent: PRO. Kidney360. 2022;3(9):1484\u20137. https:\/\/doi.org\/10.34067\/KID.0008032021","DOI":"10.34067\/KID.0008032021"},{"key":"3372_CR37","doi-asserted-by":"publisher","unstructured":"Murray BE, Arias CA, Nannini EC. Glycopeptides (vancomycin and teicoplanin), streptogramins (quinupristin-dalfopristin), lipopeptides (daptomycin), and lipoglycopeptides (telavancin). In: Mandell, Douglas, and Bennett\u2019s principles and practice of infectious diseases. Elsevier; 2015. p. 377\u2013400.e4. https:\/\/doi.org\/10.1016\/B978-1-4557-4801-3.00030-8","DOI":"10.1016\/B978-1-4557-4801-3.00030-8"},{"issue":"2","key":"3372_CR38","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30(2):239\u201345. https:\/\/doi.org\/10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"},{"key":"3372_CR39","unstructured":"Okusa MD (2024) Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury in adults [Internet]. Available from: https:\/\/www.uptodate.com\/contents\/etiology-and-diagnosis-of-prerenal-disease-and-acute-tubular-necrosis-in-acute-kidney-injury-in-adults. Accessed 02 Mar 2024"},{"issue":"2","key":"3372_CR40","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2174\/1871526521666210331164552","volume":"22","author":"H Rahmani","year":"2022","unstructured":"Rahmani H, Khalili H (2022) Prevention of vancomycin-induced nephrotoxicity; an updated review of clinical and preclinical studies. Infect Disord - Drug Targets 22(2):22\u20137. https:\/\/doi.org\/10.2174\/1871526521666210331164552","journal-title":"Infect Disord - Drug Targets"},{"issue":"10","key":"3372_CR41","doi-asserted-by":"publisher","first-page":"8601","DOI":"10.3390\/molecules16108601","volume":"16","author":"A Ra\u0161kovi\u0107","year":"2011","unstructured":"Ra\u0161kovi\u0107 A, Stilinovi\u0107 N, Kolarovi\u0107 J, Vasovi\u0107 V, Vukmirovi\u0107 S, Mikov M (2011) The protective effects of silymarin against doxorubicin-induced cardiotoxicity and hepatotoxicity in rats. Molecules 16(10):8601\u201313. https:\/\/doi.org\/10.3390\/molecules16108601","journal-title":"Molecules"},{"issue":"6","key":"3372_CR42","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1128\/AAC.01708-10","volume":"55","author":"JA Roberts","year":"2011","unstructured":"Roberts JA, Taccone FS, Udy AA, Vincent JL, Jacobs F, Lipman J (2011) Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens. Antimicrob Agents Chemother 55(6):2704\u20139. https:\/\/doi.org\/10.1128\/AAC.01708-10","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"3372_CR43","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3109\/0886022X.2010.541579","volume":"33","author":"J Roozbeh","year":"2011","unstructured":"Roozbeh J, Shahriyari B, Akmali M et al (2011) Comparative effects of silymarin and vitamin E supplementation on oxidative stress markers, and hemoglobin levels among patients on hemodialysis. Ren Fail 33(2):118\u201323. https:\/\/doi.org\/10.3109\/0886022X.2010.541579","journal-title":"Ren Fail"},{"issue":"11","key":"3372_CR44","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"MJ Rybak","year":"2020","unstructured":"Rybak MJ, Le J, Lodise TP et al (2020) Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatr. Am J Heal Pharm 77(11):835\u201364. https:\/\/doi.org\/10.1093\/ajhp\/zxaa036","journal-title":"Am J Heal Pharm"},{"issue":"7","key":"3372_CR45","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1002\/ptr.5345","volume":"29","author":"F Shahbazi","year":"2015","unstructured":"Shahbazi F, Sadighi S, Dashti-Khavidaki S et al (2015) Effect of silymarin administration on cisplatin nephrotoxicity: report from a pilot, randomized, double-blinded, placebo-controlled clinical trial. Phyther Res 29(7):1046\u201353. https:\/\/doi.org\/10.1002\/ptr.5345","journal-title":"Phyther Res"},{"key":"3372_CR46","doi-asserted-by":"crossref","unstructured":"Soleimani V, Delghandi PS, Moallem SA, Karimi G (2019) Safety and toxicity of silymarin, the major constituent of milk thistle extract: an updated review. Phyther Res 33(6):1627\u201338. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ptr.6361. Accessed 26 Apr 2024","DOI":"10.1002\/ptr.6361"},{"issue":"2","key":"3372_CR47","doi-asserted-by":"publisher","first-page":"137","DOI":"10.4103\/1735-5362.283813","volume":"15","author":"R Soltani","year":"2020","unstructured":"Soltani R, Khorvash F, Meidani M, Badri S, Alaei S, Taheri S (2020) Vitamin E in the prevention of vancomycin-induced nephrotoxicity. Res Pharm Sci 15(2):137. https:\/\/doi.org\/10.4103\/1735-5362.283813","journal-title":"Res Pharm Sci"},{"issue":"3","key":"3372_CR48","doi-asserted-by":"publisher","first-page":"279","DOI":"10.4300\/JGME-D-12-00156.1","volume":"4","author":"GM Sullivan","year":"2012","unstructured":"Sullivan GM, Feinn R (2012) Using effect size\u2014or why the P value is not enough. J Grad Med Educ 4(3):279\u201382. https:\/\/doi.org\/10.4300\/JGME-D-12-00156.1","journal-title":"J Grad Med Educ"},{"issue":"3","key":"3372_CR49","doi-asserted-by":"publisher","first-page":"144","DOI":"10.4254\/wjh.v6.i3.144","volume":"6","author":"N Vargas-Mendoza","year":"2014","unstructured":"Vargas-Mendoza N (2014) Hepatoprotective effect of silymarin. World J Hepatol 6(3):144. https:\/\/doi.org\/10.4254\/wjh.v6.i3.144","journal-title":"World J Hepatol"},{"issue":"4","key":"3372_CR50","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1177\/10600280221117993","volume":"57","author":"VL Williams","year":"2023","unstructured":"Williams VL, Smithburger PL, Imhoff AN et al (2023) Interventions, barriers, and proposed solutions associated with the implementation of a protocol that uses clinical decision support and a stress biomarker test to identify ICU patients at high-risk for drug associated acute kidney injury. Ann Pharmacother 57(4):408\u201315. https:\/\/doi.org\/10.1177\/10600280221117993","journal-title":"Ann Pharmacother"},{"issue":"4","key":"3372_CR51","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.jpba.2007.06.026","volume":"45","author":"JW Wu","year":"2007","unstructured":"Wu JW, Lin LC, Hung SC, Chi CW, Tsai TH (2007) Analysis of silibinin in rat plasma and bile for hepatobiliary excretion and oral bioavailability application. J Pharm Biomed Anal 45(4):635\u201341. https:\/\/doi.org\/10.1016\/j.jpba.2007.06.026","journal-title":"J Pharm Biomed Anal"},{"issue":"2","key":"3372_CR52","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jep.2008.10.036","volume":"121","author":"JW Wu","year":"2009","unstructured":"Wu JW, Lin LC, Tsai TH (2009) Drug\u2013drug interactions of silymarin on the perspective of pharmacokinetics. J Ethnopharmacol 121(2):185\u201393. https:\/\/doi.org\/10.1016\/j.jep.2008.10.036","journal-title":"J Ethnopharmacol"},{"issue":"1","key":"3372_CR53","doi-asserted-by":"publisher","first-page":"15","DOI":"10.21608\/aijpms.2021.52962.1014","volume":"1","author":"Z Zalat","year":"2021","unstructured":"Zalat Z, Kohaf N, Alm El-Din M, Elewa H, Abdel-Latif M (2021) Silymarin: a promising cardioprotective agent. Azhar Int J Pharm Med Sci 1(1):15\u201323. https:\/\/doi.org\/10.21608\/aijpms.2021.52962.1014","journal-title":"Azhar Int J Pharm Med Sci"},{"key":"3372_CR54","doi-asserted-by":"publisher","unstructured":"Zamoner W, Eid KZC, de Almeida LMB, et al (2022) The serum concentration of vancomycin as a diagnostic predictor of nephrotoxic acute kidney injury in critically ill patients. Antibiotics 15;11(1):112. https:\/\/doi.org\/10.3390\/antibiotics11010112","DOI":"10.3390\/antibiotics11010112"},{"issue":"3","key":"3372_CR55","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3109\/08860229809045136","volume":"20","author":"T Zima","year":"1998","unstructured":"Zima T, Kamen\u00edkov\u00e1 L, Janebov\u00e1 M, Buchar E, Crkovsk\u00e1 J, Tesar V (1998) The effect of silibinin on experimental cyclosporine nephrotoxicity. Ren Fail 20(3):471\u20139. https:\/\/doi.org\/10.3109\/08860229809045136","journal-title":"Ren Fail"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03372-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-024-03372-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03372-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T10:46:08Z","timestamp":1742294768000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-024-03372-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,23]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["3372"],"URL":"https:\/\/doi.org\/10.1007\/s00210-024-03372-5","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,23]]},"assertion":[{"value":"19 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The local Ethics Committee of Shiraz University of Medical Sciences (SUMS) approved the study protocol (reference number: IR.SUMS.REC.1402.073) and registered on the Iranian registry of clinical trials as IRCT20161010030246N6 at May 27, 2023. All participants were explained and informed for protocol of study and signed written consent forms.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Sandra L Kane-Gill receives grant funding from the National Institute of Diabetes and Digestive and Kidney Diseases R01DK121730 and U01DK130010, the National Center for Complementary and Integrative Health U54AT008909 and the Jewish Healthcare Foundation. Other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}